Oncology/Hematology Archives | Page 6 of 12 | サターラ

Publication

An Analysis on Distribution and Inter-relationships of Biomarkers Under Rivaroxaban in Japanese Patients with Non-valvular Atrial Fibrillation (CVI ARO 1)

Danielle Pillsbury2018年3月15日

Publication

A Randomized, Controlled Trial Evaluating the Efficacy and Safety of BTH1677 in Combination with Bevacizumab, Carboplatin, and Paclitaxel in First-line Treatment of Advanced Non-small Cell Lung Cancer

Danielle Pillsbury2018年2月27日

Publication

Incorporation of GSTA1 Genetic Variations into a Population Pharmacokinetic Model for IV Busulfan in Pediatric Hematopoietic Stem Cell Transplantation

Danielle Pillsbury2018年2月22日

Blog

グローバル承認申請のモデリング&シミュレーション (M&S)のための地籍調査

Analogous to how a geologist surveys the “lay of the land” to determine if oil…

Certara2018年2月16日

Publication

Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

Danielle Pillsbury2018年2月15日

Publication

Exposure-response of Veliparib to Inform Phase 2 Trial Design in Refractory or Relapsed Patients with Hematological Malignancies

Danielle Pillsbury2017年11月1日

Publication

Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach

Danielle Pillsbury2017年9月15日

Publication

Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types

Danielle Pillsbury2017年8月1日

Publication

Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients

Danielle Pillsbury2017年7月15日

Publication

Time Dependent Pharmacokinetics of Pembrolizumab in Patients with Solid Tumor and Its Correlation with Best Overall Response

Danielle Pillsbury2017年6月1日

© 2025 Certara. All Rights Reserved. | 個人情報保護

Powered by Translations.com GlobalLink Web Software